GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gyre Therapeutics Inc (NAS:GYRE) » Definitions » Total Assets

Gyre Therapeutics (Gyre Therapeutics) Total Assets : $116.5 Mil (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Gyre Therapeutics Total Assets?

Gyre Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was $116.5 Mil.

During the past 12 months, Gyre Therapeutics's average Total Assets Growth Rate was 39.40% per year.

Total Assets is connected with ROA %. Gyre Therapeutics's annualized ROA % for the quarter that ended in Dec. 2023 was -92.34%. Total Assets is also linked to Revenue through Asset Turnover. Gyre Therapeutics's Asset Turnover for the quarter that ended in Dec. 2023 was 1.13.

Gyre Therapeutics Total Assets Historical Data

The historical data trend for Gyre Therapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gyre Therapeutics Total Assets Chart

Gyre Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Total Assets
84.85 84.75 116.54

Gyre Therapeutics Semi-Annual Data
Dec21 Dec22 Dec23
Total Assets 84.85 84.75 116.54

Gyre Therapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Gyre Therapeutics's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets=Total Equity (A: Dec. 2023 )+Total Liabilities (A: Dec. 2023 )
=13.949+102.59
=116.5

Gyre Therapeutics's Total Assets for the quarter that ended in Dec. 2023 is calculated as

Total Assets=Total Equity (Q: Dec. 2023 )+Total Liabilities (Q: Dec. 2023 )
=13.949+102.59
=116.5

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gyre Therapeutics  (NAS:GYRE) Total Assets Explanation

Total Assets is connected with ROA %.

Gyre Therapeutics's annualized ROA % for the quarter that ended in Dec. 2023 is

ROA %=Net Income (Q: Dec. 2023 )/( (Total Assets (Q: Dec. 2022 )+Total Assets (Q: Dec. 2023 ))/ count )
=-92.933/( (84.753+116.539)/ 2 )
=-92.933/100.646
=-92.34 %

Note: The Net Income data used here is one times the annual (Dec. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Gyre Therapeutics's Asset Turnover for the quarter that ended in Dec. 2023 is

Asset Turnover
=Revenue (Q: Dec. 2023 )/( (Total Assets (Q: Dec. 2022 )+Total Assets (Q: Dec. 2023 ))/ count )
=113.45/( (84.753+116.539)/ 2 )
=113.45/100.646
=1.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Gyre Therapeutics Total Assets Related Terms

Thank you for viewing the detailed overview of Gyre Therapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Gyre Therapeutics (Gyre Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gyre Therapeutics Inc (NAS:GYRE) » Definitions » Total Assets
Comparable Companies
Traded in Other Exchanges
L9S:Germany
Address
12770 High Bluff Drive, Suite 150, San Diego, CA, USA, 92130
Website
https://www.gyretx.com
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.

Gyre Therapeutics (Gyre Therapeutics) Headlines

From GuruFocus

Totus Medicines Announces Appointment of Nassim Usman, Ph.D., as President & CEO and the Closing of a $66M Series B Funding

By PRNewswire • 12-15-2023